Nuritas’ notification (GRN No. 1166) covers the Fava bean (Vicia faba L.) protein hydrolysate as a protein source at a level of 2.4 grams per serving across a broad range of popular food applications, including dry-blend powders, meal replacement drinks and bars, milk analogs, ready-to-drink beverages, gummies, protein and energy bars, baked goods and more.
“We’re thrilled by this acknowledgement, as it further expands our access to an even larger customer base,” said Chris Lindsay, CCO at Nuritas. “PeptiStrong is already widely used by many fantastic partners worldwide. This confirmation will further accelerate our penetration with large multinational CPG companies.”
PeptiStrong is an ingredient with reported muscle building, anti-muscle atrophy and anti-inflammation properties, giving it a good position for sports nutrition, active lifestyles and overall health.
“Food is the main vehicle that gives everyday consumers access to nutrition and performance,” said Dr. Nora Khaldi, CEO at Nuritas. “We have built both robust safety and clinical data for PeptiStrong, our plant-based peptide ingredient, which allows it to become a staple component in a wide range of foods.
“Incorporating PeptiStrong into our diets helps give lasting energy throughout the day and enhances the nutritional effectiveness of protein, even in small amounts. This supports lean muscle mass maintenance, helping people live stronger for longer.”
She added that building and retaining muscle mass is essential for everyone, with studies showing that increasing muscle mass can help reduce all-cause mortality and significantly improve quality of life.
AI ingredient discovery
Nuritas and its Nuritas MagnifierNπΦ platform offers the potential to unlock plant-based, efficacious solutions to a myriad of health problems, with a reported success rate of up to 1,200 times that of traditional R&D in 80% less time.
The company has partnered with leading food and pharma companies including Nestle, Mars, Sumitomo Corporation and Pharmavite. Founded in Ireland, Nuritas expanded into the U.S. market in 2022 with new North American headquarters in Connecticut. Dr. Khaldi relocated to the United States to lead the company through its new growth phase.